ANIX - ITUS （Anixa Biosciences Inc.） ITUSANIXのチャート
ANIXの企業情報
| symbol | ANIx |
|---|---|
| 会社名 | Anixa Biosciences Inc （ITUS） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Medical Specialities |
| 業種 | 事業サポ―トサ―ビス 医療関連（Health Care） |
| 概要 | 事業概要 アニーシャ･バイオサイエンス(Anixa Biosciences Inc.)(旧名: ITUS Corporation)腫瘍ベースの癌の早期発見用のCchekという診断プラットフォームの開発に従事する。Cchek癌検出プラットフォームは腫瘍の中および周囲に存在し、血流に入る特定の免疫細胞の存在、不存在および量を検出することによって、悪性腫瘍に対する患者の免疫応答を測定する。身体の免疫系とがん細胞を破壊する能力の変更･強化のかわりに、腫瘍発生時に血流に起こる微妙な免疫的変化を測定する技術とプロトコルを開発する。そのプロトコルを通じて、同社は生検で確認された癌患者の末梢血および健康患者の血液と癌患者の血液を区別するバイオマーカーを検出する。 ITUSは米国の特許技術開発・ライセンス企業。特許技術の開発、取得、ライセンス供与に従事する。同社の特許は、携帯電話やモバイル通信の暗号化、電子書籍用電気泳動ディスプレイ「ePaper」、インタ―ネット電話ゲ―トウェイ、ウェブ会議の暗号化、航空会社などによるロイヤルティ―プログラムのポイント転換システムなどを含む。本社はロサンゼルス。 Anixa Biosciences Inc. is a biotechnology company developing a number of programs addressing cancer and infectious disease. Anixa's therapeutics portfolio includes a cancer immunotherapy program which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology, and a Covid-19 therapeutics program focused on inhibiting certain viral protein function. The company's vaccine portfolio includes a vaccine to prevent breast cancer, and specifically triple negative breast cancer (TNBC), the most deadly form of the disease, and a vaccine to prevent ovarian cancer. These vaccine technologies focus on immunizing against specific proteins that have been found to be expressed in certain forms of cancer. Anixa continually examines emerging technologies in complementary fields for further development and commercialization. |
| 本社所在地 | 3150 Almaden Expressway Suite 250 San Jose CA 95118 USA |
| 代表者氏名 | Amit Kumar アミットクマール |
| 代表者役職名 | Chairman of the Board President Chief Executive Officer 取締役会長兼最高経営責任者（CEO） |
| 電話番号 | +1 310-484-5200 |
| 設立年月日 | 30256 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | ―年 |
| 従業員数 | 7人 |
| url | https://www.anixa.com/ |
| nasdaq_url | https://www.nasdaq.com/symbol/anix |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -9.49194 |
| 終値（lastsale） | 5.29 |
| 時価総額（marketcap） | 98902612.34 |
| 時価総額 | 時価総額（百万ドル） 105.07230 |
| 売上高 | 売上高（百万ドル） 1.11250 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 99.73120 |
| 当期純利益 | 当期純利益（百万ドル） -10.47935 |
| 決算概要 | 決算概要 BRIEF: For the nine months ended 31 July 2018 Anixa Biosciences Inc revenues increased from $363K to $1.1M. Net loss applicable to common stockholders increased 66% to $8.7M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Stock-based Compensation in R&D increase from $213K to $2.7M (expense). |
ANIXのテクニカル分析
ANIXのニュース
Chardan Capital Markets Starts Anixa Biosciences at Buy 2022/12/23 10:52:01 Investing.com
https://www.investing.com/news/pro/chardan-capital-markets-starts-anixa-biosciences-at-buy-432SI-2969669
Anixa Biosciences Announces Presentation on Ovarian Cancer CAR-T Therapy Trial at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2022/10/10 12:30:00 PR Newswire
SAN JOSE, Calif., Oct. 10, 2022 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced a presentation outlining its ovarian cancer CAR-T therapy trial at the Society for…
Anixa Biosciences Inc. (NASDAQ:ANIX) Projected To Shrink By -114.42% Or More 2022/09/24 13:30:00 Marketing Sentinel
In last trading session, Anixa Biosciences Inc. (NASDAQ:ANIX) saw 0.41 million shares changing hands with its beta currently measuring 1.28. Company’s recent per share price level of $5.13 trading at -$0.97 or -15.90% at ring of the bell on the day assigns it a market valuation of $123.43M. That closing price of ANIX’s stock is … Anixa Biosciences Inc. (NASDAQ:ANIX) Projected To Shrink By -114.42% Or More Read More »
Why Aditxt Shares Dipped Over 58%; Here Are 82 Biggest Movers From Friday 2022/09/19 05:53:09 Benzinga
Gainers Panbela Therapeutics, Inc. (NASDAQ: PBLA ) shares jumped 53% to close at $0.58 on Friday. Applied Optoelectronics, Inc. (NASDAQ: AAOI ) shares climbed 50.4% to settle at $3.76 on Friday after the company announced the sale of its Chinese manufacturing facilities to Yuhan Optoelectronic Technology for $150 million. iBio, Inc. (NYSE: IBIO ) gained 49.8% to close at $0.46. Armata Pharmaceuticals, Inc. (NYSE: ARMP ) surged 31.2% to close at $4.21. Armata Pharmaceuticals, last month, posted a Q2 loss of $0.26 per share. Axcella Health Inc. (NASDAQ: AXLA ) jumped 29.6% to close at $2.41. Axcella Health, last month, posted a Q2 loss of $0.40 per share. Anixa Biosciences, Inc. (NASDAQ: ANIX ) gained 27.5% to close at $5.71. Lannett Company, Inc. (NYSE: LCI ) gained 25.1% to close at $0.5756. Lannett Company, last month, reported Q4 FY22 sales of $74.2 million, down from $106 million a year ago Integrated Media Technology Limited (NASDAQ: IMTE ) climbed 21.5% to close at $1.75. Decisionpoint Systems, Inc. (NASDAQ: DPSI ) rose 20.8% to close at $5.93.
Is Anixa Biosciences Inc. (NASDAQ: ANIX) Still A Buy After A 37.92% Weekly Jump? 2022/09/17 20:00:00 Marketing Sentinel
During the last session, Anixa Biosciences Inc. (NASDAQ:ANIX)’s traded shares were 0.57 million, with the beta value of the company hitting 1.28. At the end of the trading day, the stock’s price was $5.71, reflecting an intraday gain of 27.46% or $1.23. The 52-week high for the ANIX share is $5.55, that puts it up … Is Anixa Biosciences Inc. (NASDAQ: ANIX) Still A Buy After A 37.92% Weekly Jump? Read More »
Chardan Capital Markets Starts Anixa Biosciences at Buy 2022/12/23 10:52:01 Investing.com
https://www.investing.com/news/pro/chardan-capital-markets-starts-anixa-biosciences-at-buy-432SI-2969669
Anixa Biosciences Announces Presentation on Ovarian Cancer CAR-T Therapy Trial at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2022/10/10 12:30:00 PR Newswire
SAN JOSE, Calif., Oct. 10, 2022 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced a presentation outlining its ovarian cancer CAR-T therapy trial at the Society for…
Anixa Biosciences Inc. (NASDAQ:ANIX) Projected To Shrink By -114.42% Or More 2022/09/24 13:30:00 Marketing Sentinel
In last trading session, Anixa Biosciences Inc. (NASDAQ:ANIX) saw 0.41 million shares changing hands with its beta currently measuring 1.28. Company’s recent per share price level of $5.13 trading at -$0.97 or -15.90% at ring of the bell on the day assigns it a market valuation of $123.43M. That closing price of ANIX’s stock is … Anixa Biosciences Inc. (NASDAQ:ANIX) Projected To Shrink By -114.42% Or More Read More »
Why Aditxt Shares Dipped Over 58%; Here Are 82 Biggest Movers From Friday 2022/09/19 05:53:09 Benzinga
Gainers Panbela Therapeutics, Inc. (NASDAQ: PBLA ) shares jumped 53% to close at $0.58 on Friday. Applied Optoelectronics, Inc. (NASDAQ: AAOI ) shares climbed 50.4% to settle at $3.76 on Friday after the company announced the sale of its Chinese manufacturing facilities to Yuhan Optoelectronic Technology for $150 million. iBio, Inc. (NYSE: IBIO ) gained 49.8% to close at $0.46. Armata Pharmaceuticals, Inc. (NYSE: ARMP ) surged 31.2% to close at $4.21. Armata Pharmaceuticals, last month, posted a Q2 loss of $0.26 per share. Axcella Health Inc. (NASDAQ: AXLA ) jumped 29.6% to close at $2.41. Axcella Health, last month, posted a Q2 loss of $0.40 per share. Anixa Biosciences, Inc. (NASDAQ: ANIX ) gained 27.5% to close at $5.71. Lannett Company, Inc. (NYSE: LCI ) gained 25.1% to close at $0.5756. Lannett Company, last month, reported Q4 FY22 sales of $74.2 million, down from $106 million a year ago Integrated Media Technology Limited (NASDAQ: IMTE ) climbed 21.5% to close at $1.75. Decisionpoint Systems, Inc. (NASDAQ: DPSI ) rose 20.8% to close at $5.93.
Is Anixa Biosciences Inc. (NASDAQ: ANIX) Still A Buy After A 37.92% Weekly Jump? 2022/09/17 20:00:00 Marketing Sentinel
During the last session, Anixa Biosciences Inc. (NASDAQ:ANIX)’s traded shares were 0.57 million, with the beta value of the company hitting 1.28. At the end of the trading day, the stock’s price was $5.71, reflecting an intraday gain of 27.46% or $1.23. The 52-week high for the ANIX share is $5.55, that puts it up … Is Anixa Biosciences Inc. (NASDAQ: ANIX) Still A Buy After A 37.92% Weekly Jump? Read More »
Anixa Biosciences to Present at the 2022 H.C. Wainwright Global Investment Conference 2022/05/05 12:30:00 PR Newswire
SAN JOSE, Calif., May 5, 2022 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that it will present a company update at the H.C. Wainwright Global Investment…
48 Stocks Moving In Friday''s Mid-Day Session 2022/04/29 16:27:16 Benzinga
Gainers Belite Bio Inc. ADR (NASDAQ: BLTE ) shares surged 144.8% to $14.69. Belite Bio priced its 6 million ADS IPO at $6 per ADS. GTY Technology Holdings Inc. (NASDAQ: GTYH ) shares jumped 116.3% to $6.12 as the company agreed to be acquired by GI Partners. Vaxxinity, Inc. (NASDAQ: VAXX ) surged 63.3% to $6.17. Vaxxinity Executive chairman Lou Reese purchased 22,912 shares at $3.48 per share. Zymeworks Inc. (NYSE: ZYME ) shares climbed 32% to $6.55. Zymeworks confirmed it received an unsolicited, non-binding proposal from All Blue Falcons FZE and its affiliates to purchase the company for $10.50 per share. The Zymeworks board of directors will carefully review the proposal. Finch Therapeutics Group, Inc. (NASDAQ: FNCH ) gained 29.5% to $2.72. The FDA has removed the clinical hold on Finch Therapeutics Group’s investigational new drug application for CP101, an orally administered microbiome therapeutic, which is in Phase 3 study for recurrent C. difficile infection. Opiant Pharmaceuticals, Inc. (NASDAQ: OPNT ) jumped 29.2% to $23.79.
Anixa Biosciences initiates phase 1 trial of its ovarian cancer CAR-T therapy 2022/03/30 18:30:12 Seeking Alpha
Biotechnology company Anixa Biosciences <> initiated a phase 1 trial evaluating its CAR-T therapy in ovarian cancer.The early-stage trial will be held at Moffitt Cancer Center…
Anixa Biosciences Announces the Initiation of its Ovarian Cancer CAR-T Phase 1 Trial at Moffitt Cancer Center 2022/03/30 16:45:00 PR Newswire
SAN JOSE, Calif., March 30, 2022 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced the initiation of a Phase 1 trial evaluating its novel chimeric antigen receptor…